

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
- Amivantamab
- Atezolizumab Monotherapy
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- Dabrafenib + Trametinib
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
- Durvalumab
- Gemcitabine
- Nitedanib + Docetaxel
- Nivolumab
- Osimertinib
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
- Paclitaxel
- Pembrolizumab Monotherapy
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
- Pemetrexed + Platinum (Carboplatin/Cisplatin)
- RET Inhibitors (Pralsetinib, Selpercatinib)
- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy
- Palliative care only

Answer:

1a	ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	13
1b	Amivantamab	Nil

1c	Atezolizumab Monotherapy	5<
1d	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	Nil
1e	Dabrafenib + Trametinib	Nil
1f	Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	5<
1g	Durvalumab	8
1h	Gemcitabine	Nil
1i	Nitedanib + Docetaxel	5<
1j	Nivolumab	5<
1k	Osimertinib	37
1l	Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	5<
1m	Paclitaxel	9
1n	Pembrolizumab Monotherapy	50
1o	Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	5<
1p	Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)	16
1q	Pemetrexed + Platinum (Carboplatin/Cisplatin)	14
1r	RET Inhibitors (Pralsetinib, Selpercatinib)	Nil
1s	Sotorasib	5<
1t	Tepotinib	Nil
1u	Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	19
1v	Other active systemic anti-cancer therapy	6
1w	Palliative care only	N/A

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

- Atezolizumab monotherapy
- Durvalumab
- Gemcitabine
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Paclitaxel
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

Answer:

I am advised that this information is not held in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing, Midwifery and AHPs
Cc: Chief Executive